PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278814ArticlesСтатьиAPPLICATION OF CURRENT INTERNATIONAL RECOMMENDATIONS ON BRONCHIAL ASTHMA IN CLINICAL PRACTICE AND APPROACHES TO TREATMENT OF "DIFFICULT PATIENTS"ПРИМЕНЕНИЕ СОВРЕМЕННЫХ МЕЖДУНАРОДНЫХ РЕКОМЕНДАЦИЙ ПО БРОНХИАЛЬНОЙ АСТМЕ В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ И ПОДХОДЫ К ЛЕЧЕНИЮ ТРУДНЫХ ПАЦИЕНТОВKnyazheskayaNadezhda PavlovnaКняжескаяНадежда Павловна

ГОУ ВПО РГМУ

KnyazheskayaN PГОУ ВПО РГМУ20022011184NO4 (2011)№4 (2011)475123022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278814

Bronchial asthma (BA) is one of the most common diseases in modern society; ineffective treatment can significantly reduce patients' quality of life, and in some cases lead to hospitalization in the intensive care unit, and even death. In 1995, a program Global Initiative for Asthma (GINA) combining the results of various studies on the diagnosis and treatment of asthma was developed. Taking into account the recommendations of GINA-2006, the main objective of BA treatment is achievement of control of the disease, which provides absent or minimally expressed symptoms, no limitations in daily activity, no or minimal need for emergency medications, and extremely low frequency of exacerbations. The article reviews current approaches to the treatment of BA.

Бронхиальная астма (БА) - одно из наиболее распространенных заболеваний современного общества, которое при недостаточно эффективном лечении может значительно ограничивать жизнь пациентов, а в ряде случает приводить к госпитализации в реанимационное отделение и даже быть причиной смерти. В 1995 г. разработана программа Глобальная инициатива по бронхиальной астме (Global Initiative for Asthma, GINA), объединившая результаты различных научных исследований в области диагностики и лечения БА. С учетом рекомендаций, представленных в GINA-2006, основной задачей лечения БА является достижение контроля над заболеванием, который предусматривает, что у пациентов отсутствуют или минимально выражены симптомы болезни, нет ограничений в повседневной деятельности, отсутствует или минимальна потребность в препаратах неотложной помощи, частота обострений крайне низка. В статье рассматриваются современные подходы к лечению БА.

GINAbronchial asthmaGINASMART strategyleukotriene antagonistsmonoclonal antibodies against IgEбронхиальная астмастратегия SMARTантагонисты лейкотриеновмоноклональные антитела против IgEMasoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004;59:469-78.Global Initiative for Asthma. Workshop Report, 2006. http://www.ginasthma.com/download.asp?intId=217Barnes PJ. Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids. Respir Med 2001;95:S12-S16.Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002;19:182-91.Bateman ED, Boushey HA, Bousquet J, et al. Pedersen SE for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004;170:836-44.Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo. J Clin Invest 1995;96:99-106.Цой А.Н. Ингаляционные глюкокортикоиды: эффективность и безопасность // РМЖ 2001. № 9. C. 182-85.http://www.fda.gov/Palmquist M, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999.Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir1999.Tattersfield AE, Lofdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised controlled trial. Lancet 2001;357:257-61.van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996;9:1684-88.Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sci 1993.Pauwels RA, Sears NR, Cambell M, et al. Formoterol as relie medication in asthma: a world safety and effectiveness trial. Eur Respir J 2003;22:787-94.O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36.Kuna P, Peters MJ, Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone. Abstract presented at the ERS Congress 2006.Rabe K, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised, controlled, double-blind study. Lancet 2006;368:744-53.Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26(5):819-28.Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion 2004;20(9):1403-18.Klaus FR, Pizzichini E, Ställberg B, et al. Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma: A Randomized, Double-Blind Trial. Chest 2006;129:246.Holgate S, Dahlen SE. SRS-A to Leukotrienеs, 1997.O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997;111:27S-34S.Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997;17(1):22S-30S.Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study. JAMA 1998;279(15):1181.Lepeleire I, Reiss TF, Rochette F, et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997;61:83-92.O'Byrne PM. Exercise-induced bronchoconstriction: elucidating the roles of leukotrienes and prostoglandins. Pharmacotherapy 1997;17(1):31S-38S.Okudaira H. Challenge Studies of a leukotriene receptor antagonist. Chest 1997;111:46S-51S.Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007;37:197-207.Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16.Bel EH. Severe asthma Breath 2006;2:129-39.